DJIA 17,550.69 -47.51 -0.27%
NASDAQ 5,105.55 -9.84 -0.19%
S&P 500 2,093.32 -4.72 -0.22%
market minute promo

Rexahn Pharmaceuticals (NYSEMKT: RNN)

0.58 0.01 (1.75%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

RNN $0.58 1.75%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $0.59
Previous Close $0.57
Daily Range $0.56 - $0.59
52-Week Range $0.50 - $0.96
Market Cap $104.1M
P/E Ratio -14.25
Dividend (Yield) $0.00 (0.0%)
Volume 286,775
Average Daily Volume 489,342
Current FY EPS -$0.12

Sector

Healthcare

Industry

Drug Makers

Rexahn Pharmaceuticals (RNN) Description

Rexahn Pharmaceuticals Inc. is a clinical stage biopharmaceutical company developing and seeking to deliver novel cures for cancer and disorders of the central nervous system (CNS) to patients worldwide. Website: http://www.rexahn.com/

News & Commentary Rss Feed

This Week in Biotech: NW Bio Soars While Geron Goes Geronimo

Two early-stage study results, a rare hospital exemption approval in Germany, and a devastating full clinical hold for one biotech are among this week's top biotech stories.

Tuesday Sector Leaders: Oil & Gas Exploration & Production, Biotechnology Stocks

Rexahn Pharmaceuticals Awarded Patent in Japan for Novel Targeted Cancer Drug Delivery Platform

Data on Rexahn's RX-3117 in Non-Small Cell Lung Cancer Presented at 16th International Symposium of

Data on Rexahn's RX-3117 in Non-Small Cell Lung Cancer Presented at 16th International Symposium of the Purine and Pyrimidine Society

Rexahn Pharmaceuticals to Present Data on RX-3117 & Supinoxin at the 2015 American Association for C

Rexahn Pharmaceuticals to Present Data on RX-3117 & Supinoxin at the 2015 American Association for Cancer Research Annual Meeting

Rexahn Pharmaceuticals: One Biotech To Buy For A Catalyst-Filled 2015

UPDATE: MLV & Co Initiates Coverage On Rexahn Pharmaceuticals On Oncology Pipeline With Strategic Fl

UPDATE: MLV & Co Initiates Coverage On Rexahn Pharmaceuticals On Oncology Pipeline With Strategic Flexibility

Onxeo: An Upcoming Mid-Sized Pharma With Ambitions

Rexahn's Lead Drug RX-3117 Beats Lilly's Gemzar In One-To-One Face Off

Rexahn Pharmaceuticals (RNN) Jumps: Stock Rises 12.5% - Tale of the Tape

Can The Uptrend Continue for Rexahn Pharmaceuticals (RNN)? - Tale of the Tape

See More RNN News...

RNN's Top Competitors

RNN $0.58 (1.75%)
Current stock: RNN
AMGN $174.80 (-0.45%)
Current stock: AMGN
GILD $118.87 (-0.61%)
Current stock: GILD
BIIB $330.38 (1.85%)
Current stock: BIIB